课题基金 / 基金详情

INTERFERON ENHANCED CC49 MONOCLONAL ANTIBODY IN METASTATIC PROSTATE CANCER

INTERFERON ENHANCED CC49 MONOCLONAL ANTIBODY IN METASTATIC PROSTATE CANCER
干扰素增强 CC49 单克隆抗体治疗转移性前列腺癌
批准号：
6244000
负责人：
RUBY F. MEREDITH
金额：
$2.46万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-02-10 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6244000
关键词：
antitumor antibody clinical research combination cancer therapy drug screening /evaluation human subject human therapy evaluation interferons iodine male monoclonal antibody neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy prostate neoplasms radiotracer

项目摘要

项目成果

RUBY F. MEREDITH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This study is designed to determine if an antibody (CC49) which has been labeled with the radionuclide 131-I and injected into a vein, will bind primarily to tumors but not to normal tissues, allowing detection of these tumors by scanning and a therapeutic delivery of radiation. This radiolabeled antibody, 131I-CC49, is an investigational agent. The amount of radiatioactivity bound to the antibody is larger than that used for diagnostic scanning in hopes that therapeutic doses of radiation can be selectively delivered to the tumor sites. The 131I- antibody will be injected once, as a one treatment course. Interferon, an agent to stimulate cells to express the substance that the CC49 antibody reacts with, with be given before and after the antibody.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
90Y-ZEVALIN RADIOIMMUNOTHERAPY USING A MODIFIED TREATMENT REGIMEN FOR RELAPSED O
C225 WITH CHEMORADIATION FOR POST-OP HEAD AND NECK SQUAMOUS CELL CANCER
C225 WITH CHEMORADIATION FOR POST-OP HEAD AND NECK SQUAMOUS CELL CANCER
C225 WITH CHEMORADIATION FOR NSCLC
海外基金